GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Total Liabilities

Geron (STU:GON) Total Liabilities : €126.23 Mil (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Geron Total Liabilities?

Geron's Total Liabilities for the quarter that ended in Mar. 2024 was €126.23 Mil.

Geron's quarterly Total Liabilities increased from Sep. 2023 (€114.69 Mil) to Dec. 2023 (€134.00 Mil) but then declined from Dec. 2023 (€134.00 Mil) to Mar. 2024 (€126.23 Mil).

Geron's annual Total Liabilities increased from Dec. 2021 (€88.16 Mil) to Dec. 2022 (€104.39 Mil) and increased from Dec. 2022 (€104.39 Mil) to Dec. 2023 (€134.00 Mil).


Geron Total Liabilities Historical Data

The historical data trend for Geron's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Total Liabilities Chart

Geron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.33 49.14 88.16 104.39 134.00

Geron Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.30 107.87 114.69 134.00 126.23

Geron Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Geron's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=99.1+(34.898+-7.105427357601E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=134.00

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=361.368-227.369
=134.00

Geron's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=113.305+(12.924+0.00099999999999767
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=126.23

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=443.508-317.279
=126.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geron Total Liabilities Related Terms

Thank you for viewing the detailed overview of Geron's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Geron (STU:GON) Business Description

Traded in Other Exchanges
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Geron (STU:GON) Headlines

No Headlines